Azithromycin Oral Liquid Product
Phase 2Small molecule
Azithromycin Oral Liquid Product is one of 55 small molecule programs targeting Asthma. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Singulair
AstraZenecaPreclinical
Cinqair
TevaPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Formoterol Fumarate
AstraZenecaPreclinical
Azithromycin Oral Liquid Product
HHaydom Lutheran Hospital
Phase 2
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHaydom Lutheran Hospital